Resveratrol suppresses human colon cancer cell proliferation and induces apoptosis via targeting the pentose phosphate and the talin-FAK signaling pathways-A proteomic approach
- Jairam Vanamala1, 2Email author,
- Sridhar Radhakrishnan†1,
- Lavanya Reddivari†1,
- Vadiraja B Bhat3, 5 and
- Andrey Ptitsyn4
© Vanamala et al; licensee BioMed Central Ltd. 2011
Received: 11 January 2011
Accepted: 17 August 2011
Published: 17 August 2011
We and others have previously reported that resveratrol (RSV) suppresses colon cancer cell proliferation and elevates apoptosis in vitro and/or in vivo, however molecular mechanisms are not fully elucidated. Particularly, little information is available on RSV's effects on metabolic pathways and the cell-extra cellular matrix (ECM) communication that are critical for cancer cell growth. To identify important targets of RSV, we analyzed whole protein fractions from HT-29 advanced human colon cancer cell line treated with solvent control, IGF-1 (10 nM) and RSV (150 μM) using LC/MS/MS-Mud PIT (Multidimensional Protein Identification Technology).
Pentose phosphate pathway (PPP), a vital metabolic pathway for cell cycle progression, was elevated and suppressed by IGF-1 and RSV, respectively in the HT-29 cell line. Enzymatic assays confirmed RSV suppression of glucose-6 phosphate dehydrogenase (rate limiting) and transketolase, key enzymes of the PPP. RSV (150 μM) suppressed, whereas IGF-1 (10 nM) elevated focal adhesion complex (FAC) proteins, talin and pFAK, critical for the cell-ECM communication. Western blotting analyses confirmed the suppression or elevation of these proteins in HT-29 cancer cells treated with RSV or IGF-1, respectively.
Proteomic analysis enabled us to establish PPP and the talin-pFAK as targets of RSV which suppress cancer cell proliferation and induce apoptosis in the colon cancer cell line HT-29. RSV (150 μM) suppressed these pathways in the presence and absence of IGF-1, suggesting its role as a chemo-preventive agent even in obese condition.
KeywordsResveratrol Proteomics Talin Focal Adhesion Kinase (FAK) Pentose Phosphate Pathway Insulin-like Growth Factor-1 (IGF-1)
Cancer is a multifactorial disease whereas cancer cells can upregulate multiple defense mechanisms to evade drug treatments and therapies. It is therefore important to study the different mechanisms of compounds showing promise in chemopreventive efficacy to further enhance targeted therapy development. Proteomic analysis, a powerful method for discovery of new biomarkers and pathways, has recently been used in studies of obesity, diabetes, and especially cancer [1–3]. Proteomic profiling not only offers a method to study cancer but has also indeed broadened our understanding of multiple cancers. Nowadays, profiling and discovery of novel biomarkers are required for not only diagnosis but also for accurate understanding of mechanisms and causes of metabolic disorders .
Resveratrol (RSV, 3,5,4'-trihydroxy-trans-stilbene), a stilbenoid and a potent chemopreventive bioactive compound, is found in the skin of red grapes, and peanuts. RSV exerts anti-cancer properties by inhibiting three major stages of carcinogenesis, namely tumor initiation, promotion and progression . RSV has been studied extensively as a chemopreventive/anti-proliferative agent in multiple cancer types including colon and prostate cancers [5, 6]. We reported previously that RSV suppressed colon cancer cell proliferation and induced apoptosis even in the presence of IGF-1, a well-known growth factor elevated during obesity which has shown to enrich colon cancer stem cell populations [6, 7]. RSV targets p53 and IGF-1R/Wnt signaling pathways to suppress colon cancer cell proliferation and induce apoptosis. RSV interactions with p53, Akt and other effector proteins that regulate proliferation and apoptosis are well documented [6, 8–13]. However, the effects of RSV on metabolic pathways like the pentose phosphate pathway (PPP) and the cell-extracellular matrix (ECM) protein interaction, important in cancer cell growth and proliferation are not clearly understood.
High concentrations of RSV used in this study and other studies on colon cancer cell lines are quite achievable in the colon (luminal- as epithelial cells are exposed to RSV directly) with novel pectin based formulations, as most of the trans-resveratrol reaches the colon unaltered. The pectin formulation protects RSV from upper GI tract enzymes and allows for targeted release in the colon (i.e., colon-specific drug delivery system). Pectin (biopolymer) used in such formulations is safe for oral intake and almost completely degraded by colonic bacteria [14–16]. Moreover, studies with human subjects revealed that resveratrol is well tolerated even at high oral doses (daily intake of up to 5 g) without adverse effects [17–19]. Juan et al  suggested that wines with 14.3 mg/L RSV could provide a luminal concentration of around 80 μM of trans resveratrol. Thus, novel formulations that protect RSV from first-pass metabolism or presystemic metabolism during GI transit and with RSV being safely tolerated in high doses, it is quite possible to achieve 100-150 μM RSV in the colon. Thus, use of dietary bioactive compounds at pharmacological doses, is emerging as a therapeutic approach to target colon cancer in humans.
Over-activation of the IGF system is frequently observed in obese conditions and plays a key role in obesity-promoted colon cancer . Activation of the IGF system due to elevated circulating levels of IGF-1 stimulates colonocyte proliferation [21–24]. IGF-1 bound to IGF-1R activates downstream signaling pathways to promote proliferation and cell cycle progression [25, 26]. We have previously shown that RSV suppressed IGF-1 signaling via suppression of IGF-1R resulting in G1 cell cycle arrest and suppression of proliferation in HT-29 and SW480 colon cancer cells .
The metabolic pentose phosphate pathway (PPP) produces ribose-5-phosphate required for the synthesis of nucleotides. Cell proliferation requires metabolic sources for the duplication of DNA and cell size . Therefore, PPP is frequently up-regulated in cancer cells; especially in HT-29 cells where, it has been shown that the PPP is very important for cell cycle progression . This pathway is divided into two branches. The oxidative branch uses glucose-6-phosphate as a substrate to generate NADPH, NADPH acts as a reducing agent for the maintenance of reduced glutathione levels and fatty acid synthesis. On the other hand, the non-oxidative branch recycles pentose phosphates to glycolytic intermediates and generates de novo ribose-5-phosphate for nucleotide biosynthesis. Key regulatory enzymes of PPP are glucose-6-phosphate dehydrogenase (G6PDH) rate limiting enzyme in the oxidative branch and transketolase (TKT) in the non-oxidative branch [28, 29].
Cell-cell and cell-ECM interactions are important for viability and cell growth. Cell adhesion and migration contribute to normal processes such as differentiation, embryonic development, and wound healing. However, in cancer cells such processes are also significant for invasion and metastasis . Key mechanistic steps in these processes involve the extracellular protein interaction with cell specific adhesive receptors such as integrins . In cancer cells, these interactions serve as a link between extracellular and intracellular signals and regulate cell adhesion leading to invasion, proliferation, anoikis (anchorage independent apoptosis), survival and tumor progression . Even though interruption of cell-ECM adhesion is a potential strategy for cancer prevention and treatment, and in spite of the cell-ECM components frequently modulated in chemoprevention studies, not much is known about the potential effects of the bioactive compounds like RSV on cell-ECM and integrin dynamics . Talin is an integrin regulatory protein that translates the external message into regulatory intracellular signal transduction cascades. Cell-ECM interactions mediated via integrin/talin convey vital information to the cell interior to regulate cell proliferation and differentiation . Focal adhesion kinase (FAK) is another member in the family of molecules that regulates cell adhesion dynamics, stimulates multiple cellular signal transduction events leading to cell motility, proliferation and survival [35, 36]. Talin has also been suggested to mediate FAK activation upon integrin stimulation . FAK and IGF-1R have been shown to activate common pathways, leading to increased cell proliferation and survival. These studies suggest that talin-FAK signaling plays an important role in signaling initiated by integrins that translates into downstream signaling pathways .
In the present study, we used the power of functional proteomics to unravel critical components of the cancer chemoprevention ability of RSV in HT-29 advanced human colon cancer cells. The whole protein fraction of RSV (150 μM) or IGF-1 (10 nM) treated HT-29 cells was analyzed using LC/MS/MS. IGF-1 elevated and RSV suppressed G6PDH and TKT, the 2 key enzymes of oxidative and non-oxidative branches of the PPP, respectively, indicating that RSV suppressed cell cycle progression of HT-29 cells by down-regulating the PPP. Proteins in the focal adhesion complex were also found to be differentially regulated by RSV and IGF-1. RSV (150 μM) suppressed the talin and phosphorylated Fak protein levels even in the presence of IGF-1, a potent mitogen, indicating that RSV anti-cancer effects against human colon cancer cell might be partly due to disruption of cell-ECM interaction. On the basis of these results, we found the PPP and the talin-FAK signaling as critical targets of RSV.
Proteomic Analysis of HT-29 colon cancer cells treated with RSV and IGF-1
IGF-1 and RSV modulate the PPP to target cell cycle progression in human colon cancer cell line HT29
RSV suppresses while IGF-1 elevates the talin-Fak signaling pathway
The modern-day approach to cancer management is multidisciplinary, consisting of surgery, radiation therapy and chemotherapy with potential side effects. Several investigations are underway to improve the efficacy of these treatment modalities or to find new ways to treat or prevent cancer. Proteomics technology plays an important role in finding and validating biomarkers for cancer. Bioactive compounds like RSV have multiple mechanisms of action. It is vital to discover novel targets/biomarkers of chemopreventive agents like RSV that has multiple mechanisms of action so that those targets could be harnessed to develop targeted therapies. The goal of the study was to identify RSV target proteins and mechanisms implicated in its anti-neoplastic activities. The use of the proteomics technology enabled us to identify an array of proteins modulated by RSV. Although our present analysis accessed a small window in the cellular proteome, it was possible to detect RSV modulation of 1231 proteins in the HT-29 cell line. To determine if the expression of many of these proteomic markers was modified at both low and high concentrations of RSV, our confirmatory analysis included western blots and enzyme kinetic assays using RSV at concentrations 50-150 μM alone or after pre incubation with IGF-1, a mitogen elevated during obesity.
We have previously reported that at concentrations > 100 μM RSV suppressed colon cancer proliferation and up-regulated apoptosis even in the presence of IGF-1, elevated during obesity, and that has shown to enrich colon cancer stem cell populations [6, 7]. Apoptotic levels correlated with pp53 levels and suppression of proliferation transpired via attenuation of IGF-1R/Akt/Wnt signaling pathways. The present study focuses on novel targets of RSV that govern the proliferation, apoptosis and growth of a cancer cell. Using the pathway analysis software the important targets from the pool of proteins differentially altered by IGF-1 or RSV treatment were selected to devise pathways that have not been studied.
Genego Metacore software provided a basis to evaluate pathways based on differentially expressed proteins. As expected major canonical pathways affected were from the actin cytoskeleton signaling, oxidative stress response pathways, glucose metabolism, apoptosis and cell cycle etc. Among the significantly expressed proteins, G6PDH and TKT from the pentose phosphate pathway family and talin and FAK from the cytoskeleton family were found to be differentially expressed in RSV or IGF-1 treatments (Figure 1, 2 and 4). This along with the data showing that the glycolytic pathways [45, 46] and the cell-ECM interaction  to be frequently deregulated in cancer cells, fueled interest in RSV, the PPP and the talin-pFAK interaction.
Cell division is an energy-demanding process and its correct progression depends on sufficient metabolic resources to support a doubling of cell mass. Though nutrient availability is a key factor for cell proliferation, nucleotide synthesis is a rate limiting step in cancer cell replication . Ribose-5-phosphate, which is a key nucleotide component, is synthesized from glycolytic intermediates in the PPP. PPP is considered important in tumor proliferation processes because of its role in supplying tumor cells with reduced NADP and carbons for intracellular anabolic processes . In particular, the two key enzymes G6PDH and TKT have been shown to play a critical role in cancer cell cycle progression in the HT-29 cell line [28, 29].
In this study, we have demonstrated, using two different experimental approaches, that the PPP which is specifically elevated during cell cycle progression in the highly proliferating advanced human adenocarcinoma cell line HT-29 [28, 29] is further elevated by IGF-1 but suppressed by the bioactive compound RSV. Thus, a specific decrease in the activity of 2 key enzymes G6PDH and TKT, may lead to suppression of PPP that provides precursors of nucleotides for cancer cell cycle progression. Resveratrol at high concentration (150 μM) showed pronounced suppression of G6PDH and TKT in the presence of IGF-1. IGF-1 has been shown to elevate cancer cell proliferation via elevation of ROS (reactive oxygen species) . At high concentrations where resveratrol has been shown to be pro-oxidant, the pronounced effect of resveratrol on pentose phosphate pathway in the presence of IGF-1 may be due to elevated ROS levels that promotes apoptosis [20, 44]. Detailed mechanistic reason for this potentiated effect is still need to be delineated, however, based on our earlier studies we propose that this might be due to elevated suppression of pAKT, Cyclin D1, nuclear β-catenin and SP1, proteins critical for cancer cell proliferation and cell cycle progression, in the presence of IGF-1 by resveratrol .
Suppression of PPP by RSV may be via inhibition of mTORC1. Recent evidence has shown clearly that the mTORC1 controls downstream metabolic pathways like the PPP via S6K1/SREBP-1/2 . Our earlier experiments with mTOR signaling revealed that RSV activated tuberous sclerosis protein 2 (TSC-2, an mTORC1 inhibitor) and suppressed two best characterized downstream targets of mTORC1 (mammalian target of rapamycin complex 1), p70S6 kinase 1 (S6K1) and eukaryotic initiation factor 4E (eIF4E) binding protein 1 (4E-BP1) .
Talin-FAK interaction has been well established and is implicated in various cancers [49, 50]. Talin plays an essential role in integrin activation and acts as a link between cell and ECM to regulate cancer cell kinetics . Talin has been shown to engage in focal adhesion interactions with Akt signaling as the intracellular survival mechanism to confer anoikis (anchorage independent apoptosis) [51, 52] resistance and promote cancer cell invasion, especially in prostate cancer . IGF-1 has been consistently linked to increased cell proliferation and cell migration, elevating cell invasion and metastatic properties of cancer cells . Our earlier work with systems biology to identify biomarkers in metastatic progression of cancer featured talin as one of the differentially expressed genes in metastatic tumors in the context of cytoskeleton remodeling pathway . Even the current proteomics data had talin as one of the differentially expressed proteins in IGF-1 and RSV treatments (Figure 4). RSV elevated talin levels at low concentration (50 μM) and suppressed talin, and concurrently elevated apoptosis at high concentration (150 μM). This may be due to the action of RSV as an antioxidant at low concentrations and pro-oxidant at high concentrations [38, 44, 54]. Anti-oxidant action at lower doses could protect DNA damage via scavenging of ROS, whereas at high concentration RSV acts as pro-oxidant leading to oxidative breakage of cellular DNA in the presence of transition metal ions such as copper causing apoptosis [44, 54]. This could possibly explain differences in talin activity at low vs high concentrations of RSV (RSV at 50 μM is not sufficient to induce apoptosis ). However, RSV was effective in suppressing IGF-1 stimulated talin expression, irrespective of concentration used. "FAK carries out protein-protein interaction adaptor functions at sites of cell attachment to the extracellular matrix (ECM), thereby contributing to focal-adhesion 'scaffolding'. FAK also transmits adhesion-dependent and growth-factor-dependent signals into the cell interior [50, 55]." The synergistic signaling between growth-factor receptors like IGF-1R and FAK might be particularly relevant as both are often up-regulated in tumor cells [36, 55]. FAK has also been shown to work similar to the IGF-1R to activate common pathways, leading to increased proliferation and cell survival. At least in pancreatic cancer, it has been shown that dual inhibition of FAK and IGF-1R led to a synergistic decrease in cell proliferation and increase in cell detachment and apoptosis compared with inhibition of either pathway alone [56, 57]. We have shown previously that RSV inhibits IGF-1R in HT-29 cells . RSV suppressed FAK activation in the presence and absence of IGF-1. These results indicate that RSV suppression of cell proliferation and elevation of apoptosis involves modulation of FAK signaling, considering that the integrin-mediated FAK signaling regulates both proliferative and apoptotic signaling pathways [58, 59].
Proteomic profiling enabled us to identify novel targets of RSV. Our results establish PPP and the talin-pFAK as targets of RSV to suppress cancer cell proliferation and induce apoptosis in colon cancer cell line HT-29. These studies may prove germane to the envisaged use of RSV as a colon cancer chemopreventive agent as well as provide novel biomarkers to target and halt colon cancer cell kinetics.
Materials and methods
RSV and other cell culture materials were obtained from Sigma Chemical Co. (St. Louis, MO). IGF-1 was purchased from R&D Systems (Minneapolis, MN). Fetal bovine serum (FBS) was obtained from HyClone (Thermo Fisher Scientific, Inc., Pittsburgh, PA).
Colon cancer cell line HT-29, was obtained from the American Type Culture Collection (Manassas, VA). Cells were maintained at 37°C in a humidified atmosphere with 5% CO2 and grown in Dulbecco's Modified Eagle's Medium (DMEM) F-12 supplemented with 10% fetal bovine serum (FBS), 2.2 g/L sodium bicarbonate, 0.2 g/L bovine serum albumin and 10 mL/L streptomycin-penicillin mix.
HT-29 cells were seeded at a density of 1.5 × 105 cells/mL in DMEM F-12 media with 5% charcoal-stripped FBS. Next day, cells were treated with DMSO (solvent control), IGF-1 (10 nM) or RSV (150 μM) for 24 h. We found from dose response studies with IGF-1 (5-20 nM) that 10 and 20 nM IGF-1 treatments did not differ (p < 0.05) in elevating cell proliferation (data not shown). Therefore, we used 10 nM concentration of IGF-1 for our experiments, which is close to normal circulating levels. Protein was extracted into a high-salt buffer containing 1% protease and phosphatase inhibitor cocktail, and protein concentrations were determined by a BCA Protein Assay kit (Pierce, Rockford, IL). The lysate samples (200 μg) were reduced, alkylated and double digested with trypsin to generate peptides. The digested peptides were completely dried in a SpeedVac and suspended in 100 μL of 5% acetonitrile acidified with 0.1% formic acid (mobile phase A). 200 μg of peptides (40 μl) were directly loaded onto a 1 × 150 mm Poly-SEA strong cation exchange column (Michrom Bioresources, Auburn, CA) using Agilent 1200 auto sampler. Peptides were eluted to 10 fractions using 0-100 mM ammonium formate for 40 min (mobile phase B: 1 M ammonium formate, 10% Formic acid in 5% acetonitrile) and 5 fractions in 100-1000 mM ammonium formate for 10 min on Agilent 1200 Capillary LC and Analytical-fraction collector at a flow rate of 50 μL/min. Peptides were dried and reconstituted in 10 μl of 0.1% TFA for LC-MS/MS analysis.
A 3 μl volume of peptides (30% of SCX fraction) were injected into an LC/MS system consisting of an 1100 Series liquid chromatograph, HPLC-Chip Cube MS interface, and 1100 Series LC/MSD Trap XCT Ultra ion trap mass spectrometer (all Agilent Technologies, Santa Clara, CA). The system was equipped with an HPLC-Chip (Agilent Technologies) that incorporated a 160 nL enrichment column and a 150 mm × 75 μm analytical column packed with Zorbax 300SB-C18 5 μm particles. Peptides were loaded onto the enrichment column with 97% solvent A (water with 0.1% formic acid). They were then eluted with a gradient from 3% to 45% solvent B (acetonitrile with 0.1% formic acid) in 25 min, followed by a steep gradient to 90% solvent B in 5 min at a flow rate of 0.3 μl/min. The total runtime, including column reconditioning, was 35 min. The column effluent was directly coupled to an LC/MSD Trap XCT Ultra ion trap mass spectrometer from Agilent Technologies via a HPLC-Chip Cube nanospray source operated at ~1900 volts in ultra-ultra mode. The gain control (ICC) was set to 500,000 with a maximum accumulation time of 150 milliseconds. Collision induced dissociation (CID) was triggered on the six most abundant, not singly charged peptide ions in the m/z range of 450- 1500. Precursors were set in an exclusion list for 1 min after two MS/MS spectra. Results were expressed as mean for three replicate experiments for each treatment group.
CID data was searched against the NCBInr human database, using the Agilent Spectrum Mill Server software (Rev A.03.03.) installed on a HP Intel® Xeon (TM) dual processor server. Peak lists were created with the Spectrum Mill Data Extractor program with the following attributes: scans with the same precursor ± 1.4 m/z were merged within a time frame of ± 15 s. Precursor ions needed to have a minimum signal to noise value of 25. Charges up to a maximum of 7 were assigned to the precursor ion, and the 12C peak was determined by the Data Extractor. The NCBInr database was searched for tryptic peptides with a mass tolerance of ± 2.5 Da for the precursor ions and a tolerance of ± 0.7 Da for the fragment ions. Two missed cleavages were allowed. A Spectrum Mill auto validation was performed first in the protein details followed by peptide mode using default values [Minimum scores, minimum scored peak intensity (SPI), forward minus reversed score threshold, and rank 1 minus rank 2 score threshold]. All protein hits found in a distinct database search by Spectrum Mill are non-redundant.
Data scaling and normalization
Quantitative estimation of differences between physiological states by analysis of proteomics data has a number of challenges. Only a fraction of proteins actually present in each sample is identified and a still smaller fraction is quantified. Technical variation overlapped with these fractions results in substantial differences in the range of variation for identified fraction even though the overall range of variation between samples is similar (see Additional file 1, Figure S1). The resulting distribution of quantified protein abundance units has long tails of low-abundance proteins and proteins identified in only one of the samples. It is commonly advised that for MS proteomics (unlike microarrays) more technical replicates should be done in order to control variation and achieve more reliable quantitative estimation of change between samples. However, this expensive and labor-intensive "brute force" approach is not always feasible. We have taken an alternative data analysis approach which allows quantitative estimation of changes between samples with limited number of estimates. Our method is based on a reasonable assumption of little or no change in abundance for the majority of proteins in all samples. None of the experimental conditions we create in this project can be associated with lethality or high stress. There is also no indication of experiment-induced stress response in the pattern of expressed proteins. Assuming that relatively small fraction of genes have large fold changes we can apply quantile normalization algorithm, similar to that described by Bolstad et al.  for microarray normalization: x norm = F -1 (G(x)), where F is the distribution function of the actual sample, and G is the reference distribution function. We estimate G by the empirical distribution of each sample and F by using the empirical distribution of the averaged quantitative estimations of peptide abundance in samples across all experimental conditions, not just replicate groups. This approach has proven to be effective in low-replicate microarray studies [1, 61]. In our implementation G is more smoothly estimated by application of additional Savitski-Golay polynomial smoothing . In addition after scaling, we zero down scaled values for proteins not identified in particular sample. Quantile normalization scales all protein abundances in all samples to the same distribution and allows realistic estimation of fold change between experimental conditions.
Biological pathway analysis
All lists of identified proteins and respective normalized expression values were imported to GeneGo Metacore (GeneGo INC, St. Josef, MI). Analysis of overrepresentation of canonical pathways, co-regulation/protein interaction pathways and comparative network analyses are performed using intrinsic tools and pre-formed analysis pipelines of Genego Metacore.
Western blot analysis
HT-29 cells were seeded at a density of 1.5 × 105 cells/mL in Dulbecco's Modified Eagle's Medium F-12 with 5% charcoal-stripped fetal bovine serum for 24 h. Cells were treated with solvent control (DMSO), IGF-1 (10 nM), different concentrations of RSV (50, 100 and 150 μM) with and without IGF-1 for 24 h. Protein was extracted into a high-salt buffer containing 1% protease inhibitor cocktail from Sigma-Aldrich (St. Louis, MO), and protein concentrations were determined by a BCA protein assay kit from Pierce (Rockford, IL). Cell lysates (45 μg) were incubated at 98°C for 5 min and separated on 4-12% Criterion XT bis-tris gel at 120 V for 2 h in 1X XT MOPS Running Buffer (Bio-Rad Laboratories, Hercules, CA) and electrophoretically transferred to Immuno-Blot PVDF membranes (Bio-Rad) at 95 V for 35 min in tris-glycine transfer buffer with 0.025% SDS. PVDF membranes were blocked with Superblock buffer (Thermo Fisher Scientific Inc.) for 1 h at room temperature. The membranes were incubated with rabbit polyclonal anti-pFAK antibody (1:500; Cell Signaling, Danvers, MA) or mouse monoclonal anti-talin antibody (1:750; Millipore, Billerica, MA) or goat polyclonal anti-β-actin antibody (1:2500; Santa Cruz Biotechnology, Santa Cruz, CA). Membranes were also probed with respective IgG-HRP secondary antibodies from Santa Cruz Biotechnology (1:20,000; Santa Cruz, CA) and scanned using UVP imaging software (UVP BioDoc-It® Imaging System; Upland, CA). β-actin served as a loading control.
G6PDH activity was measured using Glucose-6-Phosphate Dehydrogenase assay kit (Biovision, Mountain View, CA). G6PDH activity was measured at absorbance 450 nm using the manufacturer's protocol. TKT activity was determined using the method of de la Haba et al . Briefly, protein extracts were added to a 96-well plate containing 216 mM glycylglycine, 3.3 mM xylulose-5-phosphate, 1.7 mM ribose 5-phosphate, 0.002% (w/v) cocarboxylase, 0.14 mM ß-nicotinamide adenine dinucleotide (reduced form), 15 mM magnesium chloride, 20 units α-glycerophosphate dehydrogenase/triosephosphate isomerase (based on triosephosphate isomerase units). Decrease in absorbance was recorded over 15 minutes at 340 nm and activity was determined based on the method of de la Haba et al . Protein concentration of cell extracts was determined using the BCA protein assay (Pierce) to calculate the specific activity of the enzymes.
Conflict of interests
The authors declare that they have no competing interests.
This work was supported by College of Applied Human Sciences Challenge Grant (2009-2010) and National Research Initiative Grant 2009-55200-05197 from the USDA National Institute for Food and Agriculture.
We would like to thank Scott and White Healthcare Proteomics Core Facility, Temple, TX for their help in proteomic analysis of our samples.
- Ptitsyn AA, Weil MM, Thamm DH: Systems biology approach to identification of biomarkers for metastatic progression in cancer. BMC Bioinformatics 2008,9(Suppl 9):S8. 10.1186/1471-2105-9-S9-S8PubMed CentralPubMedGoogle Scholar
- Joo JI, Kim DH, Choi JW, Yun JW: Proteomic analysis for antiobesity potential of capsaicin on white adipose tissue in rats fed with a high fat diet. J Proteome Res 2010,9(6):2977–2987. 10.1021/pr901175wPubMedGoogle Scholar
- Sundsten T, Ortsater H: Proteomics in diabetes research. Mol Cell Endocrinol 2009,297(1–2):93–103. 10.1016/j.mce.2008.06.018PubMedGoogle Scholar
- Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, et al.: Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997,275(5297):218–220. 10.1126/science.275.5297.218PubMedGoogle Scholar
- Stewart JR, Artime MC, O'Brian CA: Resveratrol: a candidate nutritional substance for prostate cancer prevention. J Nutr 2003,133(7 Suppl):2440S-2443S.PubMedGoogle Scholar
- Vanamala J, Reddivari L, Radhakrishnan S, Tarver C: Resveratrol suppresses IGF-1 induced human colon cancer cell proliferation and elevates apoptosis via suppression of IGF-1R/Wnt and activation of p53 signaling pathways. BMC Cancer 2010, 10: 238. 10.1186/1471-2407-10-238PubMed CentralPubMedGoogle Scholar
- Hart LS, Dolloff NG, Dicker DT, Koumenis C, Christensen JG, Grimberg A, El-Deiry WS: Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab. Cell Cycle 2011.,10(14):Google Scholar
- Kim AL, Zhu Y, Zhu H, Han L, Kopelovich L, Bickers DR, Athar M: Resveratrol inhibits proliferation of human epidermoid carcinoma A431 cells by modulating MEK1 and AP-1 signalling pathways. Exp Dermatol 2006,15(7):538–546. 10.1111/j.1600-0625.2006.00445.xPubMedGoogle Scholar
- Kuo PL, Chiang LC, Lin CC: Resveratrol- induced apoptosis is mediated by p53-dependent pathway in Hep G2 cells. Life Sci 2002,72(1):23–34. 10.1016/S0024-3205(02)02177-XPubMedGoogle Scholar
- Kuwajerwala N, Cifuentes E, Gautam S, Menon M, Barrack ER, Reddy GP: Resveratrol induces prostate cancer cell entry into s phase and inhibits DNA synthesis. Cancer Res 2002,62(9):2488–2492.PubMedGoogle Scholar
- Lin HY, Sun M, Tang HY, Simone TM, Wu YH, Grandis JR, Cao HJ, Davis PJ, Davis FB: Resveratrol causes COX-2- and p53-dependent apoptosis in head and neck squamous cell cancer cells. J Cell Biochem 2008,104(6):2131–2142. 10.1002/jcb.21772PubMedGoogle Scholar
- Manna SK, Mukhopadhyay A, Aggarwal BB: Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol 2000,164(12):6509–6519.PubMedGoogle Scholar
- Park JW, Choi YJ, Suh SI, Baek WK, Suh MH, Jin IN, Min DS, Woo JH, Chang JS, Passaniti A, et al.: Bcl-2 overexpression attenuates resveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 activity. Carcinogenesis 2001,22(10):1633–1639. 10.1093/carcin/22.10.1633PubMedGoogle Scholar
- Das S, Chaudhury A, Ng KY: Preparation and evaluation of zinc-pectin-chitosan composite particles for drug delivery to the colon: role of chitosan in modifying in vitro and in vivo drug release. Int J Pharm 2011,406(1–2):11–20. 10.1016/j.ijpharm.2010.12.015PubMedGoogle Scholar
- Das S, Ng KY: Impact of glutaraldehyde on in vivo colon-specific release of resveratrol from biodegradable pectin-based formulation. J Pharm Sci 2010,99(12):4903–4916. 10.1002/jps.22212PubMedGoogle Scholar
- Das S, Ng KY: Colon-specific delivery of resveratrol: optimization of multi-particulate calcium-pectinate carrier. Int J Pharm 2010,385(1–2):20–28. 10.1016/j.ijpharm.2009.10.016PubMedGoogle Scholar
- Patel KR, Brown VA, Jones DJ, Britton RG, Hemingway D, Miller AS, West KP, Booth TD, Perloff M, Crowell JA, et al.: Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res 2010,70(19):7392–7399. 10.1158/0008-5472.CAN-10-2027PubMed CentralPubMedGoogle Scholar
- Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, Booth TD, Crowell JA, Perloff M, Gescher AJ, et al.: Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007,16(6):1246–1252. 10.1158/1055-9965.EPI-07-0022PubMedGoogle Scholar
- Juan ME, Vinardell MP, Planas JM: The daily oral administration of high doses of trans-resveratrol to rats for 28 days is not harmful. J Nutr 2002,132(2):257–260.PubMedGoogle Scholar
- Juan ME, Wenzel U, Daniel H, Planas JM: Resveratrol induces apoptosis through ROS-dependent mitochondria pathway in HT-29 human colorectal carcinoma cells. J Agric Food Chem 2008,56(12):4813–4818. 10.1021/jf800175aPubMedGoogle Scholar
- LeRoith D, Roberts CT Jr: The insulin-like growth factor system and cancer. Cancer Lett 2003,195(2):127–137. 10.1016/S0304-3835(03)00159-9PubMedGoogle Scholar
- Vanamala J, Tarver CC, Murano PS: Obesity-enhanced colon cancer: functional food compounds and their mechanisms of action. Curr Cancer Drug Targets 2008,8(7):611–633. 10.2174/156800908786241087PubMedGoogle Scholar
- Ahmed RL, Thomas W, Schmitz KH: Interactions between insulin, body fat, and insulin-like growth factor axis proteins. Cancer Epidemiol Biomarkers Prev 2007,16(3):593–597. 10.1158/1055-9965.EPI-06-0775PubMedGoogle Scholar
- Frystyk J: Free insulin-like growth factors -- measurements and relationships to growth hormone secretion and glucose homeostasis. Growth Horm IGF Res 2004,14(5):337–375. 10.1016/j.ghir.2004.06.001PubMedGoogle Scholar
- Liang J, Slingerland JM: Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2003,2(4):339–345.PubMedGoogle Scholar
- Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB: Exploiting the PI3K/AKT pathway for cancer drug discovery. Nature Rev 2005,4(12):988–1004. 10.1038/nrd1902Google Scholar
- Boros LG, Lee PW, Brandes JL, Cascante M, Muscarella P, Schirmer WJ, Melvin WS, Ellison EC: Nonoxidative pentose phosphate pathways and their direct role in ribose synthesis in tumors: is cancer a disease of cellular glucose metabolism? Med Hypotheses 1998,50(1):55–59. 10.1016/S0306-9877(98)90178-5PubMedGoogle Scholar
- Vizan P, Alcarraz-Vizan G, Diaz-Moralli S, Solovjeva ON, Frederiks WM, Cascante M: Modulation of pentose phosphate pathway during cell cycle progression in human colon adenocarcinoma cell line HT29. Int J Cancer 2009,124(12):2789–2796. 10.1002/ijc.24262PubMedGoogle Scholar
- Ramos-Montoya A, Lee WN, Bassilian S, Lim S, Trebukhina RV, Kazhyna MV, Ciudad CJ, Noe V, Centelles JJ, Cascante M: Pentose phosphate cycle oxidative and nonoxidative balance: A new vulnerable target for overcoming drug resistance in cancer. Int J Cancer 2006,119(12):2733–2741. 10.1002/ijc.22227PubMedGoogle Scholar
- Albelda SM: Role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab Invest 1993,68(1):4–17.PubMedGoogle Scholar
- Stupack DG, Cheresh DA: Get a ligand, get a life: integrins, signaling and cell survival. J Cell Sci 2002,115(Pt 19):3729–3738.PubMedGoogle Scholar
- Mizejewski GJ: Role of integrins in cancer: survey of expression patterns. Proc Soc Exp Biol Med 1999,222(2):124–138. 10.1046/j.1525-1373.1999.d01-122.xPubMedGoogle Scholar
- Zhu H, Liu XW, Cai TY, Cao J, Tu CX, Lu W, He QJ, Yang B: Celastrol acts as a potent antimetastatic agent targeting beta1 integrin and inhibiting cell-extracellular matrix adhesion, in part via the p38 mitogen-activated protein kinase pathway. J Pharmacol Exp Ther 2010,334(2):489–499. 10.1124/jpet.110.165654PubMedGoogle Scholar
- Chen HC, Appeddu PA, Parsons JT, Hildebrand JD, Schaller MD, Guan JL: Interaction of focal adhesion kinase with cytoskeletal protein talin. J Biol Chem 1995,270(28):16995–16999. 10.1074/jbc.270.28.16995PubMedGoogle Scholar
- Parsons JT, Martin KH, Slack JK, Taylor JM, Weed SA: Focal adhesion kinase: a regulator of focal adhesion dynamics and cell movement. Oncogene 2000,19(49):5606–5613. 10.1038/sj.onc.1203877PubMedGoogle Scholar
- Yamamoto D, Sonoda Y, Hasegawa M, Funakoshi-Tago M, Aizu-Yokota E, Kasahara T: FAK overexpression upregulates cyclin D3 and enhances cell proliferation via the PKC and PI3-kinase-Akt pathways. Cell Signal 2003,15(6):575–583. 10.1016/S0898-6568(02)00142-0PubMedGoogle Scholar
- Radhakrishnan S, Reddivari L, Das U, Scalafani R, Vanamala J: Resveratrol potentiates grape seed extract induced human cancer cell apoptosis via activation of p53-dependent signaling pathways. Front Biosci (Elite Ed) 2011, 3: 1509–1523.Google Scholar
- Mukherjee S, Dudley JI, Das DK: Dose-dependency of resveratrol in providing health benefits. Dose Response 2010,8(4):478–500. 10.2203/dose-response.09-015.MukherjeePubMed CentralPubMedGoogle Scholar
- Choi JS, Paek AR, Kim SY, You HJ: GIPC mediates the generation of reactive oxygen species and the regulation of cancer cell proliferation by insulin-like growth factor-1/IGF-1R signaling. Cancer Lett 2010,294(2):254–263. 10.1016/j.canlet.2010.02.007PubMedGoogle Scholar
- Schlaepfer DD, Mitra SK: Multiple connections link FAK to cell motility and invasion. Curr Opin Genet Dev 2004,14(1):92–101. 10.1016/j.gde.2003.12.002PubMedGoogle Scholar
- Mitra SK, Mikolon D, Molina JE, Hsia DA, Hanson DA, Chi A, Lim ST, Bernard-Trifilo JA, Ilic D, Stupack DG, et al.: Intrinsic FAK activity and Y925 phosphorylation facilitate an angiogenic switch in tumors. Oncogene 2006,25(44):5969–5984. 10.1038/sj.onc.1209588PubMedGoogle Scholar
- Mitra SK, Schlaepfer DD: Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr Opin Cell Biol 2006,18(5):516–523. 10.1016/j.ceb.2006.08.011PubMedGoogle Scholar
- Gabarra-Niecko V, Schaller MD, Dunty JM: FAK regulates biological processes important for the pathogenesis of cancer. Cancer Metastasis Rev 2003,22(4):359–374. 10.1023/A:1023725029589PubMedGoogle Scholar
- de la Lastra CA, Villegas I: Resveratrol as an antioxidant and pro-oxidant agent: mechanisms and clinical implications. Biochem Soc Trans 2007,35(Pt 5):1156–1160.PubMedGoogle Scholar
- Vander Heiden MG, Cantley LC, Thompson CB: Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009,324(5930):1029–1033. 10.1126/science.1160809PubMed CentralPubMedGoogle Scholar
- Warburg O: On respiratory impairment in cancer cells. Science 1956,124(3215):269–270.PubMedGoogle Scholar
- Duvel K, Yecies JL, Menon S, Raman P, Lipovsky AI, Souza AL, Triantafellow E, Ma Q, Gorski R, Cleaver S, et al.: Activation of a metabolic gene regulatory network downstream of mTOR complex 1. Mol Cell 2010,39(2):171–183. 10.1016/j.molcel.2010.06.022PubMed CentralPubMedGoogle Scholar
- Vanamala J, Reddivari L: Resveratrol suppresses insulin-like growth factor-1 promoted colon cancer cell growth via activation of p53/AMPK/TSC-2 and suppression of IGF-1R/Akt/mTOR signaling pathways. AACR Meeting Abstracts: April 13 2009; Denver 2009.Google Scholar
- Sakamoto S, McCann RO, Dhir R, Kyprianou N: Talin1 promotes tumor invasion and metastasis via focal adhesion signaling and anoikis resistance. Cancer Res 2010,70(5):1885–1895. 10.1158/0008-5472.CAN-09-2833PubMed CentralPubMedGoogle Scholar
- McLean GW, Carragher NO, Avizienyte E, Evans J, Brunton VG, Frame MC: The role of focal-adhesion kinase in cancer-a new therapeutic opportunity. Nat Rev Cancer 2005,5(7):505–515. 10.1038/nrc1647PubMedGoogle Scholar
- Valentijn AJ, Zouq N, Gilmore AP: Anoikis. Biochem Soc Trans 2004,32(Pt3):421–425.PubMedGoogle Scholar
- Frisch SM, Screaton RA: Anoikis mechanisms. Curr Opin Cell Biol 2001,13(5):555–562. 10.1016/S0955-0674(00)00251-9PubMedGoogle Scholar
- Bahr C, Groner B: The IGF-1 receptor and its contributions to metastatic tumor growth-novel approaches to the inhibition of IGF-1R function. Growth Factors 2005,23(1):1–14. 10.1080/08977190400020229PubMedGoogle Scholar
- Dudley J, Das S, Mukherjee S, Das DK: Resveratrol, a unique phytoalexin present in red wine, delivers either survival signal or death signal to the ischemic myocardium depending on dose. J Nutr Biochem 2009,20(6):443–452. 10.1016/j.jnutbio.2008.05.003PubMedGoogle Scholar
- Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD: FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2000,2(5):249–256. 10.1038/35010517PubMedGoogle Scholar
- Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN: FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008,29(6):1096–1107. 10.1093/carcin/bgn026PubMed CentralPubMedGoogle Scholar
- Zheng D, Golubovskaya V, Kurenova E, Wood C, Massoll NA, Ostrov D, Cance WG, Hochwald SN: A novel strategy to inhibit FAK and IGF-1R decreases growth of pancreatic cancer xenografts. Mol Carcinog 2010,49(2):200–209.PubMed CentralPubMedGoogle Scholar
- Sonoda Y, Matsumoto Y, Funakoshi M, Yamamoto D, Hanks SK, Kasahara T: Anti-apoptotic role of focal adhesion kinase (FAK). Induction of inhibitor-of-apoptosis proteins and apoptosis suppression by the overexpression of FAK in a human leukemic cell line, HL-60. J Biol Chem 2000,275(21):16309–16315. 10.1074/jbc.275.21.16309PubMedGoogle Scholar
- Shibue T, Weinberg RA: Integrin beta1-focal adhesion kinase signaling directs the proliferation of metastatic cancer cells disseminated in the lungs. Proc Natl Acad Sci USA 2009,106(25):10290–10295. 10.1073/pnas.0904227106PubMed CentralPubMedGoogle Scholar
- Bolstad BM, Irizarry RA, Astrand M, Speed TP: A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003,19(2):185–193. 10.1093/bioinformatics/19.2.185PubMedGoogle Scholar
- Smirnova NP, Ptitsyn AA, Austin KJ, Bielefeldt-Ohmann H, Van Campen H, Han H, van Olphen AL, Hansen TR: Persistent fetal infection with bovine viral diarrhea virus differentially affects maternal blood cell signal transduction pathways. Physiol Genomics 2009,36(3):129–139.PubMed CentralPubMedGoogle Scholar
- Savitzky A, Golay M: Smoothing and differentiation of data by simplified least squares procedures. Anal Chem 1964, 36: 1627–1639. 10.1021/ac60214a047Google Scholar
- De La Haba G, Leder IG, Racker E: Crystalline transketolase from bakers' yeast: isolation and properties. J Biol Chem 1955,214(1):409–426.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.